|
|
|
| Expression and the Correlation with Prognosis of Levels of Serum CYFRA21-1 TK1 and CA15-3 in Patients with Breast Cancer |
| WU Bin, NIE Chen, TONG Meng |
| Zhongshan Hospital Affiliated to Dalian University, Liaoning Dalian 116001, China |
|
|
|
|
Abstract Objective: To explore the expression levels of serum C cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), serum thymidine kinase 1 (TK1) and carbohydrate antigen 15-3 (CA15-3) in patients with breast cancer and their correlation analysis with prognosis. Methods:The clinical data of 90 patients with breast cancer (breast cancer group) admitted from January 2013 to January 2015 were retrospectively analyzed. Another 50 patients with benign breast tumors at the same time period were selected as control group. The levels and positive rates of serum CYFRA21-1, TK1 and CA15-3 were compared between the two groups. The recurrence and metastasis at 3 years were recorded in breast cancer group. The correlation between levels of CYFRA21-1, TK1 and CA15-3 and prognosis of breast cancer was analyzed by logistic regression analysis. Results:The levels and positive rates of serum CYFRA21-1, TK1 and CA15-3 in breast cancer group were higher than those in control group (P<0.05). The levels of CYFRA21-1, TK1 and CA15-3 in recurrence group were higher than those in non-recurrence group (P<0.05), and the levels of CYFRA21-1, TK1 and CA15-3 in metastasis group were higher than those in non-metastasis group (P<0.05). Spearman analysis showed that the levels of CYFRA21-1, TK1 and CA15-3 were positively correlated with recurrence and metastasis of breast cancer (P<0.05). Conclusions:The high expression levels of serum CYFRA21-1, TK1 and CA15-3 are associated with occurrence, postoperative recurrence and metastasis of breast cancer, and can effectively predict the postoperative recurrence and metastasis
|
|
|
|
|
|
[1] 师金,梁迪,李道娟,等.全球女性乳腺癌流行情况研究[J].中国肿瘤,2017,26(9):683~690.
[2] 王丽,杨帆,孔祥顺,等.uPA、PAI-1表达与乳腺癌及预后的相关性分析[J].解放军预防医学杂志,2016,34(4):528~530.
[3] 李玉柱,张玉敏,韩龙才,等.CEA、CA153、TPS、Fer、CYFRA21-1检测在乳腺癌术后转移中的诊断价值[J].实用医学杂志,2017,33(22):3810~3814.
[4] 黄蓉,黄源,陶苹,等.不同TNM分期乳腺癌患者规范化治疗后生存期生命质量评价[J].中华肿瘤杂志,2013,35(1):71~77.
[5] 陈华丽,贺曼,毛磊.超声弹性成像联合血清糖类抗原15-3、C角蛋白19片段抗原21-1、前列腺特异性抗原水平检测对乳腺癌诊断敏感度及准确率的影响[J].中国医师进修杂志,2017,(12):1122~1126.
[6] 刘文静,毛艳,王海波.乳腺癌新辅助治疗的进展[J].临床外科杂志,2018,26(01):73~76.
[7] 刘玲玲,林芳,韩耀风,等.中国女性乳腺癌患者术后复发影响因素meta分析[J].中国公共卫生,2017,33(1):165~169.
[8] 刘美宏.乳腺癌术后复发的危险因素分析及预后指数模型构建[J].肿瘤学杂志,2017,23(7):615~618.
[9] 牛余超,姚远,马学真,等.TK1和Ki-67在三阴性乳腺癌中的表达及其临床意义[J].国际肿瘤学杂志,2016,24(6):1895~1897.
[10] 刘新唐,李玉柱,韩龙才,等.血清CA153、TPS、CYFRA21-1检测联合钼靶X摄影在乳腺癌早期诊断中的价值[J].中国热带医学,2018,18(2):150~153.
[11] 张青,甘淋.乳腺癌生物标志物的研究进展[J].生命化学,2018,38(01):85~90. |
|
|
|
2019, Vol. 25 
